IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product
development, today announced its unaudited financial and operational results for
the three and nine-month periods ended September 30, 2010.


Highlights:



--  Innovotech signs agreement for distribution of bioFILM PA(TM) test with
    LevPharm Ltd. in Israel 
--  Contract research revenue for nine-month period up 25% over 2009 
--  Agress(R) field trials show significant anti-fungal activity 



"There is a growing awareness with regard to the significant impact Innovotech's
bioFILM PA(TM) test can have on improving patient care and the associated
reduction in the cost burden to health care systems" said Dr. James Timourian,
Chief Financial Officer. "We anticipate this awareness will continue to grow as
we expand our marketing efforts both within Canada and the United States."


On July 27, 2010, Innovotech announced that it had signed an exclusive agreement
with LevPharm Ltd. of Israel to market and distribute bioFILM PA(TM) to
hospitals and clinics within Israel. LevPharm is currently in the regulatory
approval process required to distribute bioFILM PA(TM) to hospital and clinics
in Israel. It is expected that LevPharm will receive regulatory approval to
market and distribute bioFILM PA(TM) by the end of 2010. 


With regard to Agress(R), the 2010 season proved to be Innovotech's most
aggressive and diverse field season to date. Very positive results were seen in
fungal trials, specifically with regard to potatoes, where Agress(R) showed a
synergistic effect when combined with current market fungicides. This is
significant in that it demonstrates Agress'(R) unique anti-fungal activity, in
addition to its anti-bacterial capabilities, and provides an alternative
fungicide to many market products to which fungi are developing resistance. 




Financial Summary

----------------------------------------------------------------------------
                   Three-month    Three-month     Nine-month     Nine-month
                  period ended   period ended   period ended   period ended
                  September 30,  September 30,  September 30,  September 30,
($)                       2010           2009           2010           2009
----------------------------------------------------------------------------
Revenues               425,051        399,728      1,287,709        989,425
----------------------------------------------------------------------------
G&A                    326,211        262,363        936,943        759,496
----------------------------------------------------------------------------
R&D                    210,923        256,689        556,481        657,696
----------------------------------------------------------------------------
Net loss              (240,998)      (358,746)      (732,908)    (1,013,566)
----------------------------------------------------------------------------
Share Price                  -              -          $0.55          $0.90
----------------------------------------------------------------------------
Cash                         -              -        935,513      1,485,080
----------------------------------------------------------------------------



About Innovotech Inc.:

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are responsible
for a host of diseases both in human health and agriculture due to their
inherent resistance to existing antibiotics and disinfectants. There are
currently no antibiotics, disinfectants, diagnostics or regulatory standards
designed specifically for biofilm-forming organisms. 


Innovotech currently has one commercial product, bioFILM PA(TM), and one
product, Agress(R), in advanced stages of development. bioFILM PA(TM) is the
first diagnostic kit to assist physicians in the selection of the most effective
combination antibiotic treatment of patients with biofilm-based chronic lung
infections and Agress(R) is a unique, environmentally friendly seed treatment
and plant spray designed to protect crops against both bacterial and fungal
infections.


This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024